0000904454-19-000466.txt : 20190606 0000904454-19-000466.hdr.sgml : 20190606 20190606163805 ACCESSION NUMBER: 0000904454-19-000466 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190604 FILED AS OF DATE: 20190606 DATE AS OF CHANGE: 20190606 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TREU JESSE I CENTRAL INDEX KEY: 0001013425 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36332 FILM NUMBER: 19883005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001341235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-761-4904 MAIL ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: Aldexa Therapeutics, Inc. DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Neuron Systems Inc DATE OF NAME CHANGE: 20051012 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2019-06-04 0001341235 Aldeyra Therapeutics, Inc. ALDX 0001013425 TREU JESSE I C/O DOMAIN ASSOCIATES, LLC 202 CARNEGIE CENTER, SUITE 104 PRINCETON NJ 08540 1 0 0 0 Stock Option (right to buy) 7.06 2019-06-04 4 A 0 18951 0 A 2020-06-04 2029-06-03 Common Stock 18951 18951 D Stock Option (right to buy) 7.06 2019-06-04 4 A 0 1763 0 A 2020-06-04 2029-06-03 Common Stock 1763 1763 D Stock Option (right to buy) 7.06 2019-06-04 4 A 0 1653 0 A 2020-06-04 2029-06-03 Common Stock 1653 1653 D The option is exercisable in full on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer as a member of the Board of Directors through such vesting date. The option is exercisable in full on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer as the chairman of the Nominating and Corporate Governance Committee of the Board of Directors through such vesting date. The option is exercisable in full on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer as a member of the Audit Committee of the Board of Directors through such vesting date. /s/ Lisa A. Kraeutler, Attorney-in-Fact 2019-06-06